E Topol

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Multivariate sib-pair linkage analysis of longitudinal phenotypes by three step-wise analysis approaches
    Zheng Guo
    Department of Computer Science, Harbin Institute of Technology, Harbin, China
    BMC Genet 4:S68. 2003
  2. ncbi Genetic linkage analysis of longitudinal hypertension phenotypes using three summary measures
    Shaoqi Rao
    Center for Cardiovascular Genetics, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio, USA
    BMC Genet 4:S24. 2003
  3. ncbi Towards precise classification of cancers based on robust gene functional expression profiles
    Zheng Guo
    Department of Computer Science, Harbin Institute of Technology, Harbin 150001, China
    BMC Bioinformatics 6:58. 2005
  4. ncbi Physicians and the investment industry
    Eric J Topol
    Office of the Provost, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, and Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 293:2654-7. 2005
  5. ncbi Need to test the arterial inflammation hypothesis
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 106:136-40. 2002
  6. ncbi A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes
    Eric J Topol
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 41:S123-9. 2003
  7. ncbi Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization
    Eric J Topol
    Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Med 113:1-6. 2002
  8. ncbi A coxib a day won't keep the doctor away
    Eric J Topol
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Lancet 364:639-40. 2004
  9. ncbi Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
    Debabrata Mukherjee
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Arthritis Res Ther 5:8-11. 2003
  10. ncbi Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes
    Marco Roffi
    Division of Cardiology, University Hospital, Zurich, Switzerland
    Eur Heart J 25:190-8. 2004

Collaborators

Detail Information

Publications148 found, 100 shown here

  1. ncbi Multivariate sib-pair linkage analysis of longitudinal phenotypes by three step-wise analysis approaches
    Zheng Guo
    Department of Computer Science, Harbin Institute of Technology, Harbin, China
    BMC Genet 4:S68. 2003
    ....
  2. ncbi Genetic linkage analysis of longitudinal hypertension phenotypes using three summary measures
    Shaoqi Rao
    Center for Cardiovascular Genetics, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio, USA
    BMC Genet 4:S24. 2003
    ..Alternatively, we may consider using univariate transformation for linkage analysis of longitudinal repeated measures...
  3. ncbi Towards precise classification of cancers based on robust gene functional expression profiles
    Zheng Guo
    Department of Computer Science, Harbin Institute of Technology, Harbin 150001, China
    BMC Bioinformatics 6:58. 2005
    ..Therefore, there is an open space for development of the timely and relevant computational algorithms that use robust functional expression profiles towards precise classification of complex human diseases at the modular level...
  4. ncbi Physicians and the investment industry
    Eric J Topol
    Office of the Provost, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, and Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 293:2654-7. 2005
  5. ncbi Need to test the arterial inflammation hypothesis
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 106:136-40. 2002
  6. ncbi A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes
    Eric J Topol
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 41:S123-9. 2003
    ..Decisions about the three classes of antithrombotics--low-molecular-weight heparins, GP IIb/IIIa inhibitors, and thienopyridines--along with whether to adopt an early invasive strategy, should be made on an individual basis...
  7. ncbi Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization
    Eric J Topol
    Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Med 113:1-6. 2002
    ..Brief intervention with this monoclonal antibody during percutaneous coronary revascularization is associated with significant improvement of long-term survival...
  8. ncbi A coxib a day won't keep the doctor away
    Eric J Topol
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Lancet 364:639-40. 2004
  9. ncbi Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
    Debabrata Mukherjee
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Arthritis Res Ther 5:8-11. 2003
    ..The widespread use of these agents mandates prospective, randomized evaluation of the cardiovascular safety of COX-2 inhibitors...
  10. ncbi Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes
    Marco Roffi
    Division of Cardiology, University Hospital, Zurich, Switzerland
    Eur Heart J 25:190-8. 2004
    ..More efforts are needed both in terms of local drug elution as well as systemic pharmacologic therapies to further contain the excessive neointimal proliferation that characterizes the diabetic response to vascular injury...
  11. ncbi Current status and future prospects for acute myocardial infarction therapy
    Eric J Topol
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F 25, Cleveland, OH 44195, USA
    Circulation 108:III6-13. 2003
    ....
  12. ncbi Economics and quality of care for patients with acute coronary syndromes: the impending crisis
    Eric J Topol
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Ohio 44195 0001, USA
    Clin Cardiol 25:I9-15. 2002
    ..Careful consideration will need to be given to these innovative approaches to ensure they are cost effective...
  13. ncbi Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease
    Eric J Topol
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 108:399-406. 2003
    ....
  14. ncbi The rudimentary phase of personalised medicine: coronary risk scores
    Eric J Topol
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Lancet 362:1776-7. 2003
  15. ncbi A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data
    Eric J Topol
    Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Case Western Reserve University, Cleveland, Ohio, USA
    Am Heart J 149:S100-6. 2005
  16. ncbi Simon Dack Lecture. The genomic basis of myocardial infarction
    Eric J Topol
    Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
    J Am Coll Cardiol 46:1456-65. 2005
  17. ncbi Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
    E J Topol
    Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA
    Lancet 354:2019-24. 1999
    ..We assessed in a randomised trial the long-term outcomes for potent adjunctive antiplatelet therapy given at the time of coronary stenting...
  18. ncbi Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial
    E J Topol
    Department of Cardiology, The Cleveland Clinic Foundation, OH 44195, USA
    Am Heart J 139:927-33. 2000
    ..More effective antithrombotic agents are still required to treat patients at high risk for recurrent vascular events...
  19. ncbi Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
    D L Bhatt
    Department of Cardiology, F25, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    JAMA 284:1549-58. 2000
    ..Glycoprotein IIb/IIIa (Gp IIb/IIIa) receptor antagonists are potent inhibitors of platelet function that may be expected to affect favorably the natural history of ACSs...
  20. ncbi Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial
    E J Topol
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 102:1761-5. 2000
    ..One such activator, reteplase (r-PA), was compared with t-PA in the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-III Trial...
  21. ncbi Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
    E J Topol
    Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA
    N Engl J Med 344:1888-94. 2001
    ..We assessed whether there are differences in safety or efficacy between two such inhibitors, tirofiban and abciximab...
  22. ncbi Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial
    E J Topol
    Desk F25, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195, Cleveland, OH, USA
    Lancet 357:1905-14. 2001
    ..We did a randomised, open-label trial to compare the effect of reteplase alone with reteplase plus abciximab in patients with acute myocardial infarction...
  23. ncbi Recent advances in anticoagulant therapy for acute coronary syndromes
    E Topol
    Department of Cardiology, The Cleveland Clinic, Cleveland, OH 44195, USA
    Am Heart J 142:S22-9. 2001
    ..Furthermore, UFH can increase platelet activation in ACS...
  24. ncbi Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction
    E J Topol
    Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 104:2641-4. 2001
    ..Recent advances in high-throughput genomics technology have expanded our ability to catalogue allelic variants in large sets of candidate genes related to premature coronary artery disease...
  25. ncbi Primary percutaneous coronary intervention vs. fibrinolytic therapy for acute ST-elevation myocardial infarction in the elderly
    Juhana Karha
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am J Geriatr Cardiol 15:19-21. 2006
    ..The break-even incremental delay with primary percutaneous coronary intervention compared with fibrinolytic therapy is not clear at this point and will need to be elucidated by future investigation...
  26. ncbi Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 95:716-21. 2005
    ....
  27. ncbi Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy
    Jacqueline Saw
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 44:1194-9. 2004
    ..However, pretreatment was associated with a trend towards lower clinical events after PCI...
  28. ncbi Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions
    John Kao
    Division of Cardiology, University of Illinois at Chicago, Chicago, IL, USA
    Catheter Cardiovasc Interv 68:352-6. 2006
    ..heparin groups (4.2% vs. 7.8%, P = 0.16). CONCLUSION: CABG PCI using bivalirudin with provisional GPIIb/IIIa inhibition appears to provide similar safety and efficacy to heparin with GPIIb/IIIa inhibition...
  29. ncbi Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up
    Marco Roffi
    Division of Cardiology, University Hospital, Zurich, Switzerland
    Circulation 105:2730-6. 2002
    ..These findings suggest that the non-glycoprotein IIb/IIIa properties of abciximab do not translate into a discernible long-term clinical benefit among diabetic patients...
  30. ncbi Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET)
    Albert W Chan
    Department of Cardiology, Ochsner Clinic Foundation, New Orleans, Louisiana, USA
    J Am Coll Cardiol 42:1188-95. 2003
    ..CONCLUSIONS: Among patients undergoing coronary stent placement with aspirin and a GP IIb/IIIa inhibitor, clopidogrel pretreatment is associated with a reduction of death and MI irrespective of the type of GP IIb/IIIa inhibitor used...
  31. ncbi Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial
    Vivek Rajagopal
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 152:149-54. 2006
    ....
  32. ncbi Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial
    Matthews Chacko
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 151:1032.e1-7. 2006
    ....
  33. ncbi Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials
    Marco Roffi
    Division of Cardiology, University Hospital, Zurich, Switzerland
    Circulation 106:3063-7. 2002
    ..In the absence of mechanical emboli protection, this procedure is associated with high incidence of death and nonfatal ischemic events...
  34. ncbi Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Deepak L Bhatt
    Cleveland Clinic, Cleveland, USA
    N Engl J Med 354:1706-17. 2006
    ..Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes. (ClinicalTrials.gov number, NCT00050817.)...
  35. ncbi Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutan
    J Emilio Exaire
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 152:157-63. 2006
    ....
  36. ncbi Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?
    Martin J Quinn
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 106:379-85. 2002
  37. ncbi Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial
    Hitinder S Gurm
    Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Am Coll Cardiol 43:542-8. 2004
    ..Although combination therapy did not provide a survival benefit, nonfatal ischemic outcomes, including reinfarction, recurrent ischemia, and urgent revascularization, were substantially reduced...
  38. ncbi Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial
    Mitchell J Ross
    Division of Cardiology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    J Am Coll Cardiol 42:981-8. 2003
    ..Further research into novel anti-thrombotic therapies or procedural strategies is necessary for these patients...
  39. ncbi Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction
    Ronnier J Aviles
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, OH 44951, USA
    N Engl J Med 346:2047-52. 2002
    ..However, there is concern that renal dysfunction may impair the prognostic value, because cardiac troponin T may be cleared by the kidney...
  40. ncbi Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes
    Michael H Yen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Med 115:318-21. 2003
  41. ncbi Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary intervention
    Jason O Robertson
    The Department of Cardiovascular Medicine, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 97:1679-84. 2006
    ..These findings require further validation from other large, randomized trials...
  42. ncbi Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention
    Deepak P Vivekananthan
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Cardiol 94:358-60. 2004
    ..Clopidogrel pretreatment attenuated the periprocedural increase in CRP by 65% and was independently associated with an attenuation in the CRP increase in a multivariate model...
  43. ncbi Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial
    Jacqueline Saw
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 108:921-4. 2003
    ....
  44. ncbi Prognostic value of myeloperoxidase in patients with chest pain
    Marie-Luise Brennan
    Department of Cell Biology, Cleveland Clinic Foundation, Cleveland 44195, USA
    N Engl J Med 349:1595-604. 2003
    ....
  45. ncbi Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial
    Steven R Steinhubl
    Division of Cardiology, University of North Carolina, CB 7075, 338 Burnett Womack Bldg, Chapel Hill, NC 27599, USA
    JAMA 288:2411-20. 2002
    ..Also, although current clinical data suggest a benefit for beginning therapy with a clopidogrel loading dose prior to PCI, the practical application of this therapy has not been prospectively studied...
  46. ncbi Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization
    John H Chiu
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 92:582-3. 2003
    ..After adjustments in a multivariate model, a history of peripheral vascular disease was found to be associated with a two- to threefold increase in mortality at 1 year after coronary stent placement...
  47. ncbi Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model
    Zhongmin Zhou
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Arterioscler Thromb Vasc Biol 22:1598-603. 2002
    ....
  48. ncbi Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Am Coll Cardiol 45:1932-8. 2005
    ....
  49. ncbi Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition
    Leslie Cho
    Department of Cardiology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Am J Cardiol 91:742-3. 2003
  50. ncbi Challenges in the phenotypic characterisation of patients in genetic studies of coronary artery disease
    Albert K Luo
    Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
    J Med Genet 44:161-5. 2007
    ..In this paper, salient issues to facilitate research in this important field are reviewed...
  51. ncbi Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention
    Albert W Chan
    Section of Interventional Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 105:691-6. 2002
    ..65; 95% CI, 0.42 to 0.99; P=0.045). CONCLUSIONS: In this large study cohort, statin therapy among PCI patients seems to be associated with a significant mortality advantage at early and intermediate-term follow-up...
  52. ncbi Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction
    Allen Jeremias
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 143:1040-5. 2002
    ..05-1.73, P =.02). CONCLUSIONS: This analysis of patients with chronic renal insufficiency undergoing PCI suggests that postprocedural CK-MB elevation is an independent predictor of late mortality even in the presence of renal dysfunction...
  53. ncbi Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting
    Philippe L L'Allier
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, USA
    Can J Cardiol 19:1041-6. 2003
    ..Most studies have demonstrated similar outcomes and a more favourable safety profile supporting this change in practice patterns...
  54. ncbi Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Am Coll Cardiol 39:9-14. 2002
    ..Therefore, clopidogrel plus aspirin should replace ticlopidine plus aspirin as the standard antiplatelet regimen after stent deployment...
  55. ncbi Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction
    Arman T Askari
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Exp Med 197:615-24. 2003
    ..These data offer a mechanistic link between inflammation and LV remodeling by demonstrating a heretofore unrecognized role for MPO and PAI-1 in orchestrating the myocardial response to AMI...
  56. ncbi Mutation of MEF2A in an inherited disorder with features of coronary artery disease
    Lejin Wang
    Center for Cardiovascular Genetics, Department of Cardiovascular Medicine, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195, USA
    Science 302:1578-81. 2003
    ..These results identify a pathogenic gene for a familial vascular disease with features of CAD and implicate the MEF2A signaling pathway in the pathogenesis of CAD/MI...
  57. ncbi Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 97:1585-90. 2006
    ..A randomized trial comparing multivessel PCI with staged or surgical revascularization is warranted...
  58. ncbi Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial
    Ivan P Casserly
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Cardiol 92:125-9. 2003
    ....
  59. ncbi Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices
    Jose E Exaire
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am Heart J 147:31-4. 2004
    ..CONCLUSIONS: In contemporary percutaneous coronary intervention practice, with appropriate patient selection, a CD can be safely utilized despite aggressive polypharmacy for procedural anticoagulation...
  60. ncbi Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat
    Olga I Stenina
    Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Department of Molecular Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 107:3209-15. 2003
    ..This increase in TSP-1 production may be a direct response of vascular cells to glucose...
  61. ncbi Integrin alphaIIbbeta3 and its antagonism
    Martin J Quinn
    Joseph J Jacobs Center for Thrombosis and Vascular Biology, Department of Molecular Cardiology NB50, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, Ohio 44195, USA
    Arterioscler Thromb Vasc Biol 23:945-52. 2003
    ..An in-depth understanding of how antagonists engage and influence the function of alphaIIbbeta3 and platelets in the context of the new structural insights may explain its salutary and potential deleterious effects...
  62. ncbi Aspirin resistance and a single gene
    Brian K Jefferson
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 95:805-8. 2005
    ..Aspirin resistance was significantly associated with genetic variation in the platelet surface adenosine 5-diphosphate receptor gene P2Y1...
  63. ncbi Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency
    Allen Jeremias
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:1209-11. 2002
  64. ncbi Redefining risk in acute coronary syndromes using molecular medicine
    Saif Anwaruddin
    Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio, USA
    J Am Coll Cardiol 49:279-89. 2007
    ..We expound upon some of these factors and the potential they may carry in changing clinical medicine...
  65. ncbi Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury
    Zhongmin Zhou
    Experimental Interventional Laboratory, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 107:2238-43. 2003
    ..CONCLUSIONS: These findings indicate that RAGE/ligand interaction plays a key role in neointimal formation after vascular injury irrespective of diabetes status and suggest a novel target to minimize neointimal hyperplasia...
  66. ncbi Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy
    Arman Askari
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 43:1908-14. 2004
    ....
  67. ncbi Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile
    Dean J Kereiakes
    Lindner Center for Research and Education and Ohio Heart Health Center, Cincinnati, Ohio, USA
    Am J Cardiol 90:628-30. 2002
  68. ncbi The role of low-molecular-weight heparin in cardiovascular diseases
    Debabrata Mukherjee
    Division of Cardiology, University of Michigan, Ann Arbor, USA
    Prog Cardiovasc Dis 45:139-56. 2002
    ....
  69. ncbi Invisible showers
    Eric J Topol
    Cleveland Clinic Lerner College of Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Catheter Cardiovasc Interv 63:42-3. 2004
  70. ncbi Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model
    Zhongmin Zhou
    Department of Cardiology, The Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Atherosclerosis 161:153-9. 2002
    ..Anti-TNF-alpha treatment was sufficient to neutralize tissue TNF-alpha activity, reduce inflammation, but did not inhibit neointimal formation following balloon angioplasty in a rabbit atherosclerotic model...
  71. ncbi Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients < or =40 years old
    Debabrata Mukherjee
    Division of Cardiology, University of Michigan, Ann Arbor, Michigan, USA
    Am J Cardiol 92:1465-7. 2003
    ....
  72. ncbi Thrombospondin-4 and its variants: expression and differential effects on endothelial cells
    Olga I Stenina
    Department of Molecular Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 108:1514-9. 2003
    ..TSP-4 had not previously been implicated in vascular pathology, and very little information is available on its expression and functions...
  73. ncbi Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction
    Albert W Chan
    Section of Interventional Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:132-6. 2002
    ....
  74. ncbi An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
    Thomas H Wang
    Cleveland Clinic, Cleveland, OH, USA
    Eur Heart J 28:2200-7. 2007
    ..aspirin alone in the prespecified 'asymptomatic' subgroup of CHARISMA, we investigated whether dual-antiplatelet therapy may be associated with adverse cardiovascular (CV) events in a primary prevention population...
  75. ncbi Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality
    Vivek Rajagopal
    The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 94:190-2. 2004
    ....
  76. ncbi Protein carbamylation links inflammation, smoking, uremia and atherogenesis
    Zeneng Wang
    Department of Cell Biology, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Nat Med 13:1176-84. 2007
    ..We propose that protein carbamylation is a mechanism linking inflammation, smoking, uremia and coronary artery disease pathogenesis...
  77. ncbi Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy
    Arman T Askari
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Lancet 362:697-703. 2003
    ....
  78. ncbi Molecular mechanisms of myocardial infarction
    Brian K Jefferson
    The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Curr Probl Cardiol 30:333-74. 2005
    ....
  79. ncbi Aspirin and clopidogrel resistance: an emerging clinical entity
    Thomas H Wang
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Eur Heart J 27:647-54. 2006
    ....
  80. ncbi In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting?
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    J Am Coll Cardiol 49:849-54. 2007
    ....
  81. ncbi Impact of female sex on outcome after percutaneous coronary intervention
    John H Chiu
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 148:998-1002. 2004
    ..However, there is a greater incidence of post-procedural bleeding complications among women...
  82. ncbi A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease
    Patricia A Gum
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 41:961-5. 2003
    ..06, p = 0.009). CONCLUSIONS: This study demonstrates the natural history of aspirin resistance in a stable population, documenting a greater than threefold increase in the risk of major adverse events associated with aspirin resistance...
  83. ncbi The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am Heart J 150:89-93. 2005
    ....
  84. ncbi Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes
    Deepak L Bhatt
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Ave, Desk F25, Cleveland, OH 44195, USA
    Circulation 112:906-15; discussion 923. 2005
  85. ncbi Platelet, not endothelial, P-selectin is required for neointimal formation after vascular injury
    Kai Wang
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Arterioscler Thromb Vasc Biol 25:1584-9. 2005
    ..This study was designed to determine whether P-selectin expression on platelet, endothelial, or both surfaces is critical to the inflammatory response and neointimal formation after arterial injury...
  86. ncbi Facilitated PCI in patients with ST-elevation myocardial infarction
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic, F25, 9500 Euclid Ave, Cleveland, OH 44195, USA
    N Engl J Med 358:2205-17. 2008
    ....
  87. ncbi 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial
    Stephen G Ellis
    Cleveland Clinic, Department of Cardiovascular Medicine, Cleveland, Ohio 44195, USA
    JACC Cardiovasc Interv 2:909-16. 2009
    ..The aim of this report was to evaluate 12-month outcomes of facilitated percutaneous coronary intervention (PCI) in the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial...
  88. ncbi Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, OH 44195, USA
    Am Heart J 143:847-53. 2002
    ..This agent has not yet been tested with stenting or in combination with platelet glycoprotein IIb/IIIa antagonists...
  89. ncbi Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model
    Kai Wang
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Cardiovasc Pharmacol 45:61-7. 2005
    ..We conclude that celecoxib decreases the inflammatory response and intimal hyperplasia following vascular injury, possibly through inhibition of MCP-1 expression, implying a pivotal role of inflammation in the pathogenesis of restenosis...
  90. ncbi Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial
    Sorin J Brener
    Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Am Coll Cardiol 39:377-86. 2002
    ..This study was designed to test the hypothesis that eptifibatide and reduced-dose tissue plasminogen activator (t-PA) will enhance infarct artery patency at 60 min in patients with acute myocardial infarction (AMI)...
  91. ncbi Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44122, USA
    J Invasive Cardiol 19:287-90. 2007
    ..The relationship between target vessel revascularization (TVR) and ischemic events in patients treated with aspirin and clopidogrel or aspirin alone from 1 month to 1 year after PCI has not been studied...
  92. ncbi Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy
    W H Wilson Tang
    Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, OH 44195, USA
    Am Heart J 153:36-41. 2007
    ..The comparative prognostic values between NT-proBNP levels and left ventricular ejection fraction (LVEF) in the nonurgent PCI setting are unclear...
  93. ncbi Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model
    Kai Wang
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, OH 44195, USA
    J Pharmacol Exp Ther 317:37-43. 2006
    ....
  94. ncbi Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F 25, Cleveland, OH 44195 USA
    Eur Heart J 27:413-8. 2006
    ..The optimal revascularization strategy in patients with symptomatic multivessel coronary artery disease (CAD) and previous coronary artery bypass grafting (CABG) remains unknown...
  95. ncbi Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 294:2581-6. 2005
    ....
  96. ncbi Comparison of long-term survival following non-Q-wave creatine kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus those not so treated
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:751-3. 2002
  97. ncbi Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1982-8. 2007
    ..The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD)...
  98. ncbi A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 150:401. 2005
    ..We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis...
  99. ncbi Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study
    Deepak L Bhatt
    Cleveland Clinic, Department of Cardiovascular Medicine, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am Heart J 154:137-43. 2007
    ..We sought to determine whether peroxisome proliferator-activated receptor gamma agonists had any beneficial effect on patients with metabolic syndrome undergoing percutaneous coronary intervention (PCI)...
  100. ncbi Polymorphisms A387P in thrombospondin-4 and N700S in thrombospondin-1 perturb calcium binding sites
    Olga I Stenina
    Department of Molecular Cardiology, Joseph J Jacobs Center for Thrombosis, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    FASEB J 19:1893-5. 2005
    ..Since these substitutions exert the opposite effects on Ca2+ binding, a decrease in TSP-1 and an increase in TSP-4, the two TSP variants are likely to influence cardiovascular functions in distinct but yet pathogenic ways...
  101. ncbi Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting
    Stephen G Ellis
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:937-40. 2002
    ..06, p = 0.33), which is consistent with the results of prior randomized trials. ACE inhibitors appear to decrease late revascularization, possibly due to a reduction in restenosis after coronary stenting...